BRAF and melanoma: One unexpected off‐target effect of vemurafenib was the rapid development of cutaneous lesions including squamous cell carcinomas (SCC) (frequently of the rare keratoacanthoma type), actinic keratoses, and secondary (non‐BRAF‐mutant) melanomas (Gibney et al., 2013; Su et al., 2012).